Skye Bioscience, Inc.

What they do

Skye Bioscience is a clinical-stage biotechnology company developing nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1), for obesity, overweight, and metabolic disorders. The company has no approved products and no revenue; it operates solely through research and development, including a Phase 2a trial (CBeyond) and an expansion study. Nimacimab was acquired through the Bird Rock Bio acquisition in August 2023.

Recent performance

For the three months ended June 30, 2026, R&D expenses fell 73% to $3.9M from $14.3M, driven by termination of clinical activities and pausing of nimacimab R&D. General and administrative expenses were roughly flat at $3.9M, with legal fees up $1.55M due to strategic alternatives and litigation. The company recorded a $3.25M legal contingency charge in Q2 2026. For 2025, net loss was $55.9M with operating cash flow of -$43.1M. As of June 30, 2026, cash was $8.1M, total assets $11.0M, and shareholders' equity was -$497,307.

Strategy

Management is pausing all R&D activities on nimacimab to evaluate strategic options, including a proposed transaction agreement. Prior strategy centered on advancing nimacimab as a combination therapy with incretin-based drugs, exploring metabolic indications, and developing next-generation GPCR-targeting molecules. The company also highlighted a proof-of-concept antigen-peptide conjugate platform (nimacimab-GLP1RA) as a potential future direction. Cost-cutting measures and headcount reductions are being implemented to preserve cash.

Risks

• Going concern and cash runway — The auditor has expressed substantial doubt about the company's ability to continue as a going concern, with limited cash ($8.1M) and ongoing losses.
• Dependence on nimacimab — The business is heavily dependent on the clinical success and regulatory approval of nimacimab, which is still in early-stage development.
• Clinical trial uncertainty — Early clinical results may not predict later outcomes; the 200 mg monotherapy dose failed to achieve targeted weight loss, and higher-dose expansion data are pending.
• Legal contingencies — The company faces litigation, including the 'Cunning Lawsuit,' and recorded a $3.25M legal contingency charge in Q2 2026.

Outlook

Management expects to report topline data from the CBeyond Expansion Study (Part C) in Q4 2026, testing higher IV doses (400 mg and 600 mg). The company is using FDA Type C meeting minutes to finalize a Phase 2b protocol for nimacimab as monotherapy and in combination with incretin therapy. However, near-term focus is on evaluating strategic alternatives, with all R&D paused, so the timeline for further development is uncertain.